These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

416 related articles for article (PubMed ID: 32507099)

  • 1. NEPA as antiemetic prophylaxis after failure of 5HT
    Valerio MR; Gebbia V; Borsellino N; Vecchia M; Serretta V; Pardo S; Cipolla C; Galanti D
    J Oncol Pharm Pract; 2021 Apr; 27(3):609-613. PubMed ID: 32507099
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Safety of Oral NEPA (Netupitant/Palonosetron), the First Fixed-Combination Antiemetic, in Patients With Gynecological Cancers Receiving Platinum-Based Chemotherapy.
    Bošnjak SM; Stamatovic L; Borroni ME; Rizzi G; Jordan K
    Int J Gynecol Cancer; 2018 Jul; 28(6):1153-1161. PubMed ID: 29794499
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy.
    Aapro M; Rugo H; Rossi G; Rizzi G; Borroni ME; Bondarenko I; Sarosiek T; Oprean C; Cardona-Huerta S; Lorusso V; Karthaus M; Schwartzberg L; Grunberg S
    Ann Oncol; 2014 Jul; 25(7):1328-1333. PubMed ID: 24603643
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NEPA (netupitant/palonosetron) for the antiemetic prophylaxis of nausea and vomiting induced by chemotherapy (CINV) with Folfirinox and Folfoxiri even during the COVID-19 pandemic: a real-life study.
    De Luca R; Volpe C; Mistretta O; Paci R; Ferrera G; Caputo V; Rosati G; Cicero G
    Eur Rev Med Pharmacol Sci; 2021 Aug; 25(16):5310-5317. PubMed ID: 34486707
    [TBL] [Abstract][Full Text] [Related]  

  • 5. One shot NEPA plus dexamethasone to prevent multiple-day chemotherapy in sarcoma patients.
    Badalamenti G; Incorvaia L; Messina C; Musso E; Casarin A; Ricciardi MR; De Luca I; Bazan V; Russo A
    Support Care Cancer; 2019 Sep; 27(9):3593-3597. PubMed ID: 30762142
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NEPA, a fixed oral combination of netupitant and palonosetron, improves control of chemotherapy-induced nausea and vomiting (CINV) over multiple cycles of chemotherapy: results of a randomized, double-blind, phase 3 trial versus oral palonosetron.
    Aapro M; Karthaus M; Schwartzberg L; Bondarenko I; Sarosiek T; Oprean C; Cardona-Huerta S; Hansen V; Rossi G; Rizzi G; Borroni ME; Rugo H
    Support Care Cancer; 2017 Apr; 25(4):1127-1135. PubMed ID: 27885469
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Netupitant/palonosetron (NEPA) and dexamethasone for prevention of emesis in breast cancer patients receiving adjuvant anthracycline plus cyclophosphamide: a multi-cycle, phase II study.
    Caputo R; Cazzaniga ME; Sbrana A; Torrisi R; Paris I; Giordano M; Montesarchio V; Guarneri V; Amaducci L; Bilancia D; Cilenti G; Fabi A; Collovà E; Schirone A; Bonizzoni E; Celio L; De Placido S; De Laurentiis M
    BMC Cancer; 2020 Mar; 20(1):232. PubMed ID: 32188417
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of NEPA, a fixed antiemetic combination of netupitant and palonosetron, vs a 3-day aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV) in Chinese patients receiving highly emetogenic chemotherapy (HEC) in a randomized Phase 3 study.
    Chang J; Chen G; Wang D; Wang G; Lu S; Feng J; Li W; Li P; Lanzarotti C; Chessari S; Zhang L
    Cancer Med; 2020 Jul; 9(14):5134-5142. PubMed ID: 32472742
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Timing flexibility of oral NEPA, netupitant-palonosetron combination, administration for the prevention of chemotherapy-induced nausea and vomiting (CINV).
    Baron-Hay S; Aapro M; Bernareggi A; Schwartzberg L
    Support Care Cancer; 2019 Apr; 27(4):1309-1317. PubMed ID: 30685793
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Pragmatic Study Evaluating NEPA Versus Aprepitant for Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Moderately Emetogenic Chemotherapy.
    Zelek L; Debourdeau P; Bourgeois H; Wagner JP; Brocard F; Lefeuvre-Plesse C; Chauffert B; Leheurteur M; Bachet JB; Simon H; Mayeur D; Scotté F
    Oncologist; 2021 Oct; 26(10):e1870-e1879. PubMed ID: 34216177
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized phase III study evaluating the efficacy of single-dose NEPA, a fixed antiemetic combination of netupitant and palonosetron, versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC).
    Zhang L; Lu S; Feng J; Dechaphunkul A; Chang J; Wang D; Chessari S; Lanzarotti C; Jordan K; Aapro M
    Ann Oncol; 2018 Feb; 29(2):452-458. PubMed ID: 29092012
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of NEPA (netupitant/palonosetron) across multiple cycles of chemotherapy in breast cancer patients: A subanalysis from two phase III trials.
    Rugo HS; Rossi G; Rizzi G; Aapro M
    Breast; 2017 Jun; 33():76-82. PubMed ID: 28285236
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of palonosetron plus dexamethasone in preventing chemotherapy-induced nausea and emesis in patients receiving carboplatin-based chemotherapy for gynecologic cancers: a phase II study by the West Japan Gynecologic Oncology Group (WJGOG 131).
    Nishio S; Aihara S; Shimokawa M; Fujishita A; Taniguchi S; Hachisuga T; Yanazume S; Kobayashi H; Murakami F; Numa F; Kotera K; Okura N; Toki N; Yokoyama M; Ushijima K
    J Gynecol Oncol; 2018 Sep; 29(5):e77. PubMed ID: 30022637
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Netupitant/Palonosetron: A Review in Chemotherapy-Induced Nausea and Vomiting.
    Shirley M
    Drugs; 2021 Jul; 81(11):1331-1342. PubMed ID: 34292534
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study.
    Hesketh PJ; Rossi G; Rizzi G; Palmas M; Alyasova A; Bondarenko I; Lisyanskaya A; Gralla RJ
    Ann Oncol; 2014 Jul; 25(7):1340-1346. PubMed ID: 24608196
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Palonosetron with aprepitant plus dexamethasone to prevent chemotherapy-induced nausea and vomiting during gemcitabine/cisplatin in urothelial cancer patients.
    Kitamura H; Takahashi A; Hotta H; Kato R; Kunishima Y; Takei F; Horita H; Masumori N;
    Int J Urol; 2015 Oct; 22(10):911-4. PubMed ID: 26087891
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The efficacy of triplet antiemetic therapy with 0.75 mg of palonosetron for chemotherapy-induced nausea and vomiting in lung cancer patients receiving highly emetogenic chemotherapy.
    Miura S; Watanabe S; Sato K; Makino M; Kobayashi O; Miyao H; Iwashima A; Okajima M; Tanaka J; Tanaka H; Kagamu H; Yokoyama A; Narita I; Yoshizawa H
    Support Care Cancer; 2013 Sep; 21(9):2575-81. PubMed ID: 23644992
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Budget impact of netupitant/palonosetron for the prevention of chemotherapy-induced nausea and vomiting.
    Park SH; Binder G; Corman S; Botteman M
    J Med Econ; 2019 Aug; 22(8):840-847. PubMed ID: 31094589
    [No Abstract]   [Full Text] [Related]  

  • 19. Preventing chemotherapy-induced nausea and vomiting in patients with lung cancer: efficacy of NEPA (netupitant-palonosetron), the first combination antiemetic.
    Hesketh PJ; Palmas M; Nicolas P
    Support Care Cancer; 2018 Apr; 26(4):1151-1159. PubMed ID: 29080920
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase III study evaluating the safety and efficacy of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting over repeated cycles of chemotherapy.
    Gralla RJ; Bosnjak SM; Hontsa A; Balser C; Rizzi G; Rossi G; Borroni ME; Jordan K
    Ann Oncol; 2014 Jul; 25(7):1333-1339. PubMed ID: 24631949
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.